Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

st and telephone replays of the conference call will be available approximately two hours after the completion of the call through July 4, 2007. Please dial 416-695-5800 or 800-408-3053 and enter code 3225539 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, is ongoing.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:4/24/2015)... 24, 2015 Hospira, Inc. (NYSE: ... of biosimilar therapies, spoke about the importance of extrapolation ... Generics Association (EGA) annual European Biosimilars Group conference in ... also announced the publication of a pivotal white paper ... full promise of biosimilars." Speaking at ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... IRVINE, Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.12 per diluted share.  Net income for ... or $0.56 per diluted share, and non-GAAP net income ... Net sales for the quarter ended March 31, 2015 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
...  Reportlinker.com announces that a new market ... catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This ... development strategies by the two mechanism/target/effect ...
... Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals ... equipment that will assist IDRI as it designs and ... the developing world. IDRI will apply the gift as ... tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza. ...
Cached Medicine Technology:Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 2Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 3Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 4Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 5GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:4/24/2015)... The first step to transforming one’s life ... meditation and yoga teacher Stine Koppernæs, meditation and changing ... that allow her to experience more peace and freedom ... teacher since 2006, and through the years she has ... , “I love sharing this way of finding true, ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Anchor Health ... Medical Field Professionals, today announced their exclusive agreement with ... Long Term Care Insurance distribution partner. , Anchor has ... Term Care Insurance benefits for associations, and is currently ... its Long Term Care Insurance member benefit. , ...
(Date:4/24/2015)... 24, 2015 “Kind,” “selfless,” “the voice ... the ways Denise Weiner described pediatric oncology nurse Laura ... her daughter, Alexa, during her five-year battle with a ... bone marrow transplant and numerous experimental treatments, Vasquez continued ... Alexa when she was not in the hospital and ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... MA (PRWEB) April 24, 2015 ... prime location for patients looking to enroll in ... is less than a mile away from Alternative ... is scheduled to open this summer. With ... to be the go-to place for residents of ...
Breaking Medicine News(10 mins):Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:Medical Doctor from Salem Massachusetts Supports the Medical Marijuana Industry 2
... towards food has cost us a fortune as no one really ... dedicated university researcher spent part of his lifetime organizing his students ... waste at every stage along the food chain. His findings have ... ever eaten. ,Studies have show that in agriculture, where ...
... A protein that protects the body from tissue damage has ... protein helps the body's healthy cells survive the effects of ... found to encourage the growth of tumors in mice following ... urethane, a lung-specific carcinogen, on two sets of mice, which ...
... More people in the West are turning to yoga now to ... provides a good feeling and enormous satisfaction," Kumud Schramm of the ... regularly you become more alert and are not thrown out of ... Frankfurt. , ,For the past two years, there has been ...
... for Cellular and Molecular Biology (CCMB), Hyderabad has unraveled ... detecting the mechanisms that prevent cancer in human beings//. ... Bhadra have been instrumental behind this novel finding to ... for centuries. ,They hope that silencing segments of ...
... being investigated to find out how effectively it can be ... successful, it might turn out to be an ideal alternative ... ,It has been a problem of concern as regarding what ... therapy. This study has been initiated taking into account the ...
... study that is published in the current issue of ... that make popcorn are at a heightened health risk ... WV, Bethesda, MD, and San Francisco, CA, administered a ... employed by a popcorn factory. , ,Fifty-nine workers ...
Cached Medicine News:
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes)....
... Biosense Webster offers a wide range ... meet the special needs of children and ... is handcrafted to demanding specifications using only ... that incorporates proven wire braiding and extrusion ...
... Medical offers patient monitoring products for ... and medium acuity monitoring. The Envoy ... product. The Enmove monitor offers ... to complement the Envoy. The ...
... An Ankle Brachial Index (ABI) is one of the most simple to perform and useful vascular tests ... in order to perform a complete ABI. ... ... ...
Medicine Products: